Increase ACR Test Uptake with Digital Screening
Improve outcomes for people at risk for chronic kidney disease, close care gaps, reduce costs.
Funded Programmes Across the UK
Healthy.io in partnership with NHSx, the Accelerated Access Collaborative and the National Institute for Health Research, have received funding to enable digital kidney health testing across the UK.
This nationally significant programme uses tried and tested technology to deliver a COVID safe service, which aims to improve outcomes in kidney health testing for people with diabetes and other cohorts at risk for chronic kidney disease. We are seeking immediate expressions of interest from PCNs, CCGs, STPs, and other providers which specialise in this area of healthcare.
Smartphone-enabled testing has shown to increase uptake from 0% to 72% among consented untested patients, whilst minimising the traditional workload each practice has to take on to fulfill this care process.
Key Benefits
- Meet national guidelines around ACR testing
- Address health inequalities by reaching untested populations
- Reduce backlogs in chronic disease management
- Empower patients to take an active role in their care
- Integrate results direct to the EPR
- Drive population health savings
- Adopt a new testing model, with 50-100% of costs funded
Minuteful test kits measure ACR (albumin to creatine ratio) to identify early signs of kidney damage
Patient scans the urine dipstick using a smartphone app, which guides them via a chatbot
Results are analysed and uploaded to SystmOne or EMIS workflows in real time, for doctor review
found the test 'easy' or 'very
easy' to use
preferred testing remotely
vs. testing at the clinic
would recommend this service
to a friend
The Smartphone as a Clinical-Grade Medical Device
The CKD early detection service increases adherence to annual urinary albumin to creatinine ratio (ACR) testing, which is known to be beneficial in the early detection and prevention of CKD, is recommended by NICE, and monitored by the National Diabetes Audit.
The test is built around the existing ACR point of care dipstick. It measures semi quantitative analysis of microalbumin (10 – 150 mg/L), creatinine (10 – 300mg/dL) and albumin to creatinine ratio (mg/g).
Results are expressed as ACR normal (<30mg/g), ACR abnormal (30-300mg/g) or ACR high abnormal (>300mg/g).
The product is CE marked, GDPR compliant, and follows industry standards for privacy and safety.
Barking and Dagenham CCG
Call for Expressions of Interest
Subsidised deployments of the service are available to innovative, forward-thinking partners interested in empowering their patients and improving care through an evidence-based, time-saving, and patient-focused digital technology.
The availability of funding varies regionally ranging from 50% to 100% subsidies. Please express your interest before 1pm on 11th June. Once submitted, we will be in touch to discuss the next steps towards releasing these benefits for your patient population at scale.
Please contact [email protected] with any questions.
By providing this information, you consent to receive relevant content from Healthy.io. (You may opt out at any point.) For more information, visit our Privacy Policy.
- Judith Shore, Michelle Green, Andrew Hardy & Deborah Livesey (2019): The compliance and cost-effectiveness of smartphone urinalysis albumin screening for people with diabetes in England, Expert Review of Pharmacoeconomics & Outcomes Research, DOI: 10.1080/14737167.2019.1650024
